-- 据周二提交给澳大利亚证券交易所的文件显示，Cleo Diagnostics（ASX：COV）已与生命科学公司Bio-Techne启动一项分阶段的生产和开发项目，以支持其卵巢癌检测试剂盒的生产。 文件称，该项目将生产用于分析验证和评估公司在美国开展的临床研究样本所需的检测试剂盒。 文件还指出，分析验证和临床样本检测的数据将构成公司向美国食品药品监督管理局（FDA）提交510(k)申请的核心证据。 周二午盘交易中，Cleo Diagnostics股价上涨8%。
Related Articles
Asia
Raytron Tech's Q1 Profit Surges 228%, Revenue Jumps 71%; Shares Up 5%
Raytron Technology's (SHA:688002) net profit attributable to shareholders in the first quarter surged 228% to 478.7 million yuan from 145.8 million yuan a year earlier, according to a Shanghai bourse filing on Tuesday.Earnings per share soared 211% year on year to 0.98 yuan from 0.32 yuan.Operating revenue jumped 71% to 1.94 billion yuan from 1.14 billion yuan in the prior year.Raytron manufactures uncooled infrared thermal imaging products. Its shares jumped 5% during the afternoon trade.
$SHA:688002
Asia
Jefferies Adjusts Perfect World's Price Target to 19.80 Yuan from 20.60 Yuan, Keeps at Buy
$SHE:002624
Asia
BP Plastics Strikes Off Dormant Unit; Shares Drop 3%
BP Plastics (KLSE:BPPLAS) unit BPPLAS Plantation has been struck off and deemed dissolved from the Companies Commission of Malaysia, according to a Monday Malaysian bourse filing.Shares fell about 3% in Tuesday's midday trade.BPPLAS Plantation was dormant with no future business plans, was dissolved as part of a cost and administrative streamlining exercise.The group said the dissolution will not have a material impact on earnings or net assets.
$KLSE:BPPLAS